Experimental gene therapy targets common cancer protein
NCT ID NCT05035407
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial tested a new type of immunotherapy for people with advanced cancers that carry a specific protein called KK-LC-1. The treatment involved collecting a patient's own immune cells, modifying them in the lab to better recognize and attack cancer cells, and infusing them back along with a drug to help them survive. The study aimed to find a safe dose and was open to adults with gastric, breast, cervical, lung, or other epithelial cancers that tested positive for KK-LC-1.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KITA-KYUSHU LUNG CANCER ANTIGEN 1, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KK-LC-1 T cell receptor (TCR) gene therapy plus aldesleukin (IL-2)
What this could lead to
If successful, this could point toward a new treatment option for several hard-to-treat cancers that express the KK-LC-1 protein.
What could go wrong
This is an early phase 1 trial focused on safety, not effectiveness. The trial was terminated, so results may be limited. Side effects from chemotherapy, cell infusion, and aldesleukin can be severe.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.